CERo Therapeutics (CERO) Institutional Ownership $8.43 +0.05 (+0.54%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for CERo Therapeutics (NASDAQ:CERO)CurrentInstitutional OwnershipPercentage29.64%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$1.11BNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$36.66M Get CERO Insider Trade Alerts Want to know when executives and insiders are buying or selling CERo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CERO Institutional Buying and Selling by Quarter CERo Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/15/2025Armistice Capital LLC312,000$228K0.0%N/A5.798% 4/29/2025Avantax Planning Partners Inc.74,321$54K0.0%-97.1%2.453% 4/8/2025 Parallel Advisors LLC220,000$161K0.0%N/A7.261% 2/17/2025ARCH Venture Management LLC9,393,561$564K0.2%+550.4%626.237% 2/7/2025Avantax Planning Partners Inc.2,585,151$155K0.0%+89.9%171.999% (Data available from 1/1/2016 forward) CERO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CERO shares? During the previous two years, the following institutional investors and hedge funds held shares of CERo Therapeutics shares: ARCH Venture Management LLC ($564K), Armistice Capital LLC ($228K), and Parallel Advisors LLC ($161K), Avantax Planning Partners Inc. ($54K).Learn more on CERo Therapeutics' institutional investors. What percentage of CERo Therapeutics' stock is owned by institutional investors? 29.64% of CERo Therapeutics' stock is owned by institutional investors. Learn more on CERO's institutional investor holdings. Which institutional investors have been buying CERo Therapeutics' stock? The following institutional investors have purchased CERo Therapeutics' stock in the last 24 months: ARCH Venture Management LLC ($7.95M), Avantax Planning Partners Inc. ($1.22M), Armistice Capital LLC ($312K), and Parallel Advisors LLC ($220K). How much institutional buying is happening at CERo Therapeutics? Institutional investors have bought a total of 9,705,286 shares in the last 24 months. This purchase volume represents approximately $1.11B in transactions. Which of CERo Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold CERo Therapeutics stock in the last 24 months: Avantax Planning Partners Inc. ($2.51M). How much institutional selling is happening at CERo Therapeutics? Institutional investors have sold a total of 2,510,830 shares in the last 24 months. This volume of shares sold represents approximately $36.66M in transactions. Related Companies ME Major Shareholders PMN Major Shareholders LPTX Major Shareholders ALVR Major Shareholders BCLI Major Shareholders IMNN Major Shareholders NXTC Major Shareholders BTAI Major Shareholders PHIO Major Shareholders ABP Major Shareholders This page (NASDAQ:CERO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERO Stock Alerts